AVXL logo

AVXLAnavex Life Sciences Corp

$2.66
$0.25
(8.87%)
Today
Closed $2.57
$0.0886
(3.45%)
After Hours
Updated: 07:21 PM EDT
Reported EarningsFeb 9
Mkt Cap$261.33M
Vol942,449.00
News
all
press releases
Anavex Life Sciences (AVXL) to Release Earnings on Tuesday
Anavex Life Sciences (NASDAQ:AVXL) will be releasing its Q2 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-anavex-life-sciences-corp-stock...
MarketBeat
News Placeholder
More News
News Placeholder
Anavex Life Sciences Corp. (NASDAQ:AVXL) Receives Consensus Rating of "Hold" from Analysts
Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) have received an average recommendation of 'Hold' from the five brokerages that are currently covering the firm, Marketbeat...
MarketBeat
News Placeholder
Anavex Life Sciences (NASDAQ:AVXL) Coverage Initiated by Analysts at Rodman & Renshaw
Rodman & Renshaw initiated coverage on shares of Anavex Life Sciences in a report on Monday. They set a 'buy' rating and a $20.00 target price on the stock...
MarketBeat
News Placeholder
Anavex Life Sciences (NASDAQ:AVXL) Share Price Passes Below 200 Day Moving Average - Time to Sell?
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Below Two Hundred Day Moving Average - Here's Why...
MarketBeat
News Placeholder
Anavex Life Sciences (NASDAQ:AVXL) Share Price Passes Below 200-Day Moving Average - Time to Sell?
Anavex Life Sciences (NASDAQ:AVXL) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened...
MarketBeat
News Placeholder
Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham Conference
Anavex Life Sciences (NASDAQ:AVXL) is prioritizing upcoming pivotal studies and continued regulatory engagement as it seeks potential pathways to market authorization for its oral central nervous...
MarketBeat
News Placeholder
Anavex Life Sciences' (AVXL) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital reissued a "buy" rating and issued a $24.00 price target on shares of Anavex Life Sciences in a research note on Tuesday...
MarketBeat
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire
News Placeholder
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
Anavex shares fall after pulling EU filing for blarcamesine in Alzheimer's; EMA feedback prompts more data work.read more...
Benzinga
News Placeholder
AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug
Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.